A Randomized, Double-Blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg TID) in Patients with Symptomatic Pulmonary Hypertension associated with Idiopathic Interstitial Pneumonias (IIP). University of Miami